Skip to content
Open Data Finder
Open Government Canada

Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Potential Risk of Bone-Related Side Effects

Published by Health Canada | Santé Canada

About this dataset

The minerals stored within the bones help provide strength. Bones that have fewer minerals (less bone mineral density) are more likely to become brittle and break (fracture). A safety review was carried out by Health Canada to evaluate the risk of bone-related side effects of using SGLT2 inhibitors. The review was triggered by a notice about international reports of bone-related side effects experienced in patients taking the SGLT2 inhibitor canagliflozin.

Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) … · Open Data Finder